Tirofiban Hydrochloride – Platelet GP IIb/IIIa Inhibitor
Abstract
Tirofiban is a peptidomimetic (nonpeptide) platelet glycoprotein IIb/IIIa inhibitor. Clinical studies have shown that tirofiban plus heparin is more effective than heparin alone in patients with acute coronary syndromes. Tirofiban has also been shown to be effective in reducing ischemic complications associated with percutaneous coronary intervention. Tirofiban (in combination with aspirin, clopidogrel and heparin) is indicated for use in patients undergoing PCI as well as for the treatment of unstable angina or non-Q-wave myocardial infarction.
Tirofiban is a competitive inhibitor of glycoprotein (GP) IIb/IIIa preventing the binding of fibrinogen, von Willebrand factor (vWF), and other adhesive ligands to the GP IIb/IIIa receptor on activated platelets.
Tirofiban is administered intravenously. The recommended regimen of 0.4 mcg/kg/min IV for 30 minutes followed by 0.1 mcg/ kg/min IV thereafter produces a peak tirofiban plasma concentration that is similar to the steady state concentration during the infusion.
When publishing with Kerala Medicial Journal (KMJ), authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Work includes the material submitted for publication and any other related material submitted to KMJ. In the event that KMJ does not publish said work, the author(s) will be so notified and all rights assigned hereunder will revert to the author(s).
The assignment of rights to KMJ includes but is not expressly limited to rights to edit, publish, reproduce, distribute copies, include in indexes or search databases in print, electronic, or other media, whether or not in use at the time of execution of this agreement.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
The author(s) hereby represents and warrants that they are sole author(s) of the work, that all authors have participated in and agree with the content and conclusions of the work, that the work is original, and does not infringe upon any copyright, propriety, or personal right of any third party, and that no part of it nor any work based on substantially similar data has been submitted to another publication.